MX2011011881A - Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. - Google Patents

Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Info

Publication number
MX2011011881A
MX2011011881A MX2011011881A MX2011011881A MX2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A
Authority
MX
Mexico
Prior art keywords
drug
diabetes
derivatives
delphinidin
prediabetes
Prior art date
Application number
MX2011011881A
Other languages
Spanish (es)
Inventor
Agustin Lugo Radillo
Original Assignee
Agustin Lugo Radillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agustin Lugo Radillo filed Critical Agustin Lugo Radillo
Priority to MX2011011881A priority Critical patent/MX2011011881A/en
Priority to PCT/MX2012/000102 priority patent/WO2013058644A1/en
Publication of MX2011011881A publication Critical patent/MX2011011881A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7

Abstract

Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. Said drug has the effect of lowering plasma glucose concentration following administration. Said drug intended for the treatment of prediabetes and diabetes can contain delphinidin or any of the derivatives thereof, individually or in multiple combinations. In addition, the drug can contain a combination of other pharmaceutical products. Moreover, the drug can be used via any route of administration. Said drug containing delphinidin or any of the derivatives thereof and intended for the treatment of prediabetes and diabetes can be administered to any eukaryotic organism, including humans.
MX2011011881A 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. MX2011011881A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.
PCT/MX2012/000102 WO2013058644A1 (en) 2011-10-17 2012-10-15 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Publications (1)

Publication Number Publication Date
MX2011011881A true MX2011011881A (en) 2013-04-17

Family

ID=48141151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Country Status (2)

Country Link
MX (1) MX2011011881A (en)
WO (1) WO2013058644A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234957A1 (en) * 2003-03-03 2006-10-19 Takanori Tsuda Adiponectin expression promoter
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US20090176718A1 (en) * 2007-10-31 2009-07-09 David Ribnicky Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome

Also Published As

Publication number Publication date
WO2013058644A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
NZ702663A (en) Nuclear transport modulators and uses thereof
PH12013501790B1 (en) Use of dpp iv inhibitors
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
MX2014002171A (en) Combination treatments for hepatitis c.
MX2015000990A (en) Glucagon analogues.
PL2731947T3 (en) Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
IN2014KN02583A (en)
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
EP3162804A8 (en) New benzodiazepine derivative and use thereof
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2013013808A (en) Expandable devices coated with a rapamycin composition.
BR102012028120B8 (en) USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
MX2011011879A (en) Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes.
MX2011011881A (en) Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.
WO2011106378A3 (en) Oral b12 therapy
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
UA109944U (en) PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL
MX2011011880A (en) Use of derivatives of betanidine and isobetanidine for the preparation of a drug for the treatment of prediabetes and diabetes.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal